covid-trials.pdf (496.76 kB)
Download file

The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19-a Rapid Review of International Registry Data.

Download (496.76 kB)
journal contribution
posted on 29.09.2020, 08:42 by Rupert Major, Haresh Selvaskandan, Yahya Mostafa Makkeyah, Katherine Hull, Apexa Kuverji, Matthew Graham-Brown
The exclusion of patients with CKD from clinical trials has been a barrier to therapeutic advancement in CKD for the last two decades.1 These inequities were highlighted by the Kidney Disease Improving Global Outcomes Controversies Conference, with the ambition of ensuring that individuals with CKD are included in relevant clinical trials.2 The coronavirus disease 2019 (COVID-19) pandemic’s global effect has led to rapid clinical trial registration and commencement in search of effective treatments. Individuals with CKD are at higher risk of COVID-19–related mortality.3 It is unclear, however, if these individuals have equitable access to clinical trial recruitment. Therefore, we aimed to assess the CKD-related inclusion and exclusion criteria for COVID-19 trials.

Funding

National Institute for Health Research Academic Clinical Lectureship award

National Institute for Health Research Academic Clinical Fellow award

Kidney Research UK TF_009_20181123

History

Citation

Journal of the American Society of Nephrology, Vol. 31, Issue 9, September 2020

Author affiliation

Department of Health Sciences, University of Leicester

Version

AM (Accepted Manuscript)

Published in

Journal of the American Society of Nephrology

Volume

31

Issue

9

Publisher

American Society of Nephrology (ASN)

issn

1046-6673

eissn

1533-3450

Copyright date

2020

Available date

08/09/2020

Spatial coverage

United States

Language

eng